These findings suggest that survivin‐2B peptide vaccines are effective in preventing cancer relapse by targeting cancer stem‐like cells, with future directions aimed at developing multipeptide “cocktail” vaccines to reduce the risk of immune evasion. The gene discussed is BIRC5; the disease is cancer.